Navigation Links
Capability of curry component to treat disease merits US patent
Date:6/12/2012

A U.S patent issued today to the University of Rochester and two other entities for the use of compounds related to a popular spice in the fight against cancer, acne, baldness, and other medical conditions.

The patent centers on compounds related to curcumin, the compound that is the main ingredient of the spice turmeric and a central ingredient of curry. The patent is for research led by Chawnshang Chang, Ph.D., director of the George Whipple Laboratory for Cancer Research at the University of Rochester Medical Center.

Chang is one of many researchers worldwide investigating the potential biomedical benefits of compounds related to curcumin, the spice that typically gives mustard and curry their bright yellow colors. Two dozen patents dating back to 2004 have been issued to the University for Chang's work on compounds related to curcumin, which is a member of the ginger family of spices. Patents have been issued in China, Europe, New Zealand, Korea, Singapore, Hong Kong, and Australia, as well as the United States.

Chang's work at the University is licensed to AndroScience Corp. of San Diego, a biotech company co-founded by Chang. The University owns a stake in the company.

The patent focuses on the potential for compounds related to curcumin to fight prostate, bladder, liver, and other forms of cancer related to male hormones, as well as conditions like acne, baldness, enlarged prostate, and excessive growth of body hair. Those conditions and others involve the androgen receptor, which is best known as the molecule through which the hormone testosterone acts in both men and women.

Chang is developing molecules known as "androgen receptor degradation enhancers" that would degrade the androgen receptor. The work aims at developing compounds that treat conditions like prostate cancer and acne more effectively, with fewer side effects, than current medications.

For centuries, curcumin has been used to treat a variety of ills in Asia. Chang notes that ginger, a family of spices that includes curcumin, is widely used in China as a folk medicine to treat male-pattern baldness. As a youngster growing up in Taiwan, Chang was well aware of that tradition. He later became an expert on the androgen receptor; he and other scientists have shown that compounds related to curcumin exert powerful effects through this receptor.

"It's exciting and gratifying to be part of the broad effort to learn more about how compounds like ginger and curcumin exert potential health effects, which are well recognized in China and other cultures, and to try to harness them to treat people with diseases like prostate cancer," said Chang, who is also a faculty member in the departments of Urology and Pathology and the James P. Wilmot Cancer Center.

Chang's laboratory, in collaboration with scientists at the University of North Carolina at Chapel Hill and AndroScience, has screened hundreds of compounds for their activity involving the androgen receptor. One of the most promising is ASC-J9, a synthetic chemical compound that is a derivative of curcumin. Significantly, however, ASC-J9 has been chemically modified compared to its natural counterpart to make it much more powerful.

In 2009 AndroScience announced the results of a clinical trial showing that ASC-J9 as a cream to treat acne is safe and effective. With funding from the National Institutes of Health, the company is also studying the development of an oral treatment against a rare neuromuscular condition known as Kennedy disease.

Today's patent was awarded to the University of Rochester, to AndroScience, and to the University of North Carolina at Chapel Hill.


'/>"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis
2. Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo
3. Depressed Teens Who Respond to Treatment Less Likely to Abuse Drugs
4. Mount Sinai researchers develop a multi-target approach to treating tumors
5. Nanomedicines promise fewer side effects in treating cancer
6. Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
7. Control of disease activity and biologic treatment increase life expectency in RA patients
8. Treatment with anti-TNFs can increase the risk of shingles by up to 75 percent
9. 1 in 5 Americans Has Untreated Cavities: CDC
10. Mayo Clinic, youth mental health experts, publish new guidelines to treat childhood aggression
11. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Milwaukee, WI (PRWEB) , ... March 29, 2017 , ... ... as its exclusive provider of co-op eligible dealer websites for its network of more ... line of professional landscaping and agricultural equipment including rotary and flail mowers and cutters, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an ... Pet Protect Law that assists dog owners in creating legally-enforceable pet trusts ... in taking the natural next step to protect their new companion. Says Evan Dunbar, ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Youth Futures International ... success and feedback from high school and college students who have participated in the ... July 7-23 and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a ... at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben ... the visionary leader in the training of physicians, scientists, and members of the ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... insight into the challenges employers face in trying to balance both short-term and ... benefits programs? Adding to the growing complexity, companies are finding that the ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Designers of primary cell wearable medical and ... 50% and extend battery life with the MAX20310 ultra-low ... (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... voltage of just 0.7V for new high-energy density battery ... well as the more common Alkaline battery architecture. With ...
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology: